First human test of new eye injection for blinding condition

NCT ID NCT07230834

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This is an early-stage study testing the safety and side effects of an experimental drug called pozelimab when injected into the eye. It involves about 54 people who have geographic atrophy, a condition that slowly damages the retina and causes vision loss. The main goal is to see how well people tolerate the injection and to measure how much of the drug stays in the eye and bloodstream.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY (GA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Austin Retina Associates
RECRUITING

Austin, Texas, 78705, United States
Colorado Retina Associates
RECRUITING

Lakewood, Colorado, 80228, United States
Ophthalmic Consultants of Boston
RECRUITING

East Weymouth, Massachusetts, 02189, United States
Retina Consultants Texas
RECRUITING

The Woodlands, Texas, 77384, United States

Conditions

Explore the condition pages connected to this study.

GEOGRAPHIC ATROPHY (GA)